CurrentUnitedHealthcarePolicy CS081NM.C

Nerve Graft to Restore Erectile Function During Radical Prostatectomy (for New Mexico Only)

UnitedHealthcare medical policy (New Mexico only) addressing coverage of autologous or allogenic nerve grafts (e.g., sural nerve grafting) to restore erectile function during or after radical prostatectomy. Defines coverage rationale, cites clinical evidence, and lists applicable procedure codes for reference.

Policy Summary

PayerUnitedHealthcare

PolicyNerve Graft to Restore Erectile Function During Radical Prostatectomy (for New Mexico Only)

Policy CodePolicy CS081NM.C

Change TypeClarified (supporting information updated)

Effective DateDec 1, 2025

Next Review Date

Key ActionThis medical policy only applies to the state of New Mexico; providers must reference applicable federal, state, or contractual requirements which may govern coverage in place of this policy.

SourceLink

POLICY UPDATE CHANGES

Updated Description of Services, Clinical Evidence, FDA, and References sections; archived previous policy version CS081NM.B.

1States Applicable

Not coveredCoverage Status

2Reference CPT unlisted codes

Coverage Summary

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

UnitedHealthcare medical policy (New Mexico only) addressing coverage of autologous or allogenic nerve grafts (e.g., sural nerve grafting) to restore erectile function during or after radical prostatectomy. The policy defines the coverage rationale, cites clinical evidence, and lists applicable procedure codes for reference.

Policy Metadata

policy_numberCS081NM.C

subjectNerve grafting to restore erectile function during radical prostatectomy

effective_date2025-12-01

last_review2025-12-01

statusCURRENT

Not covered — cosmetic / not medically necessary for restoration of erectile function with nerve grafting.

Coverage rationale: Autologous (e.g., sural) or allogenic nerve grafts to restore erectile function during or after radical prostatectomy are unproven and not medically necessary due to insufficient evidence of efficacy.

Coding (reference)

Reference Procedure Codes (listed for reference only)CPT

55899	Unlisted procedure, male genital system
64999	Unlisted procedure, nervous system

Billing Rule

Reference codes only

The listed CPT codes are provided for reference only and their presence in this policy does not imply that services described by these codes are covered or reimbursable under applicable plans.

55899
64999

Provider Actions & Documentation

Documentation Required

State-specific applicability

This medical policy only applies to the state of New Mexico; providers must reference applicable federal, state, or contractual requirements which may govern coverage in place of this policy.

Applies to New Mexico only.
Providers must follow applicable federal, state, or contractual coverage requirements.

Denial Risk

Denial likely for surgical nerve grafting to restore erectile function

Claims for nerve grafting procedures when intended to restore erectile function after radical prostatectomy are unlikely to be approved under this policy because autologous or allogenic nerve grafts for this indication are considered unproven and not medically necessary due to insufficient evidence of efficacy.

Autologous nerve grafting (e.g., sural nerve grafting) for erectile function
Allogenic nerve grafting for erectile function

Background & Evidence Summary

Nerve grafting (for example, sural nerve grafting) has been proposed to bridge resected cavernous nerves during radical prostatectomy to restore spontaneous erectile function when neurovascular bundles are resected. The procedure involves harvesting a donor nerve (commonly the sural nerve) and grafting it to the distal and proximal ends of the resected cavernous nerve.

The policy concludes there is insufficient high-quality evidence demonstrating that nerve grafting improves erectile function after radical prostatectomy; available randomized data were stopped early for lack of benefit and observational studies are limited by design.

A randomized trial (Davis et al., 2009) was stopped early after an interim analysis showed no increase in potency at two years with unilateral sural nerve grafting compared to control; the trial was terminated due to slow accrual and a low probability of showing a benefit.

Multiple case series and nonrandomized observational studies report mixed results but are limited by small sample sizes, lack of comparison groups, baseline differences between groups, and potential bias; these limitations prevent definitive conclusions about efficacy.

Systematic and narrative reviews have noted promising signals in some microsurgical approaches but emphasize that the studies lack adequate comparators and sufficient size to make firm claims.

NCCN (2025) states that replacement of resected nerves with nerve grafts does not appear to be effective for patients undergoing wide resection of the neurovascular bundles.

Definitions

Sural nerve graft (SNG)Autologous nerve graft harvested from the sural nerve in the lower leg used to bridge resected cavernous nerves during radical prostatectomy.